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Introduction: To delineate an optimal clinical target volume (CTV) 
for gastroesophageal junction (GEJ) cancers by comparing locore-
gional versus extended locoregional radiation (RT) volumes.
Materials: This retrospective analysis examined 222 patients (111 
matched pairs treated with locoregional versus extended locore-
gional RT) with nonmetastatic GEJ carcinomas treated with concur-
rent chemoradiation ± surgery. The CTV for locoregional volumes 
was defined as gross tumor volume + elective coverage of first-ech-
elon nodes and sometimes the celiac axis. The CTV for extended 
locoregional volumes was defined as gross tumor volume + elective 
coverage of celiac and splenic (±porta) nodes. Variables used for 
matching included sex, stage, performance status, histology, receipt 
of induction chemotherapy, type of concurrent chemotherapy, RT 
modality, receipt of surgery, type of surgery, and Siewert classifica-
tion. Regression models stratified by matched pairs were fit to esti-
mate effect of RT volume on clinical endpoints.
Results: Adjusting p values for multiple testing, patients treated with 
extended locoregional versus locoregional RT had increased odds of 
grade 2+ acute chemoradiation-associated gastrointestinal toxicity 
(odds ratio: 2.92, adj. p = 0.0447). However, differing RT volumes 
were not significantly associated with postoperative complication rates, 
pathologic T-stage, frequency of positive perigastric/regional nodes on 
surgical specimen, distant-metastases progression-free survival, locore-
gional progression-free survival, or overall survival (adj. p > 0.05). Of 
the patients who did (n = 124) and did not (n = 72) receive elective 
celiac RT, two (1.6%) and two patients (2.8%), respectively, relapsed in 
the celiac nodes. No patients failed in the splenic or porta nodes.
Conclusions: Most GEJ cancers can be safely treated without elec-
tive inclusion of splenic/porta nodes.
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Although radiation (RT) in the management of nonmeta-static esophageal cancer has led to significant improve-
ments in survival,1–4 it remains unclear how to define the 
optimal clinical target volume (CTV), especially for gas-
troesophageal junction (GEJ) carcinomas. Part of the 
uncertainty in target definition arises from the controversy 
regarding whether GEJ carcinomas should be classified 
as gastric or esophageal carcinomas.5–9 Although the most 
recent AJCC classification changed the categorization of all 
tumors located within 5 cm below the GEJ and infiltrating 
the junction as esophageal cancers, several studies suggest 
that GEJ carcinomas should be more appropriately classi-
fied as gastric cancers.7–9
The challenge with this uncertainty in classification is 
that the recommended target volumes for gastric cancers dif-
fer from that recommended for esophageal cancers. Based on 
National Comprehensive Cancer Network (NCCN) guide-
lines, the CTV for GEJ esophageal tumors should include 
elective coverage of the first-echelon nodes including para-
esophageal, lesser curvature, and celiac axis. For more gas-
tric-centric tumors at the GEJ, however, NCCN also suggests 
additional CTV coverage of regional splenic/porta nodes if 
there is extension into or involvement of the body/middle-
third of the stomach.
Questions thus remain regarding the optimal CTV for 
GEJ carcinomas—should these tumors be contoured liked 
esophageal tumors with locoregional RT volumes (coverage 
of first-echelon nodes ± celiac axis), or like gastric tumors 
with more extensive locoregional RT volumes (additional 
splenic and porta nodal coverage)? Advocates of extended 
locoregional nodal RT are concerned about the risk of nodal 
relapse, whereas opponents of extended locoregional nodal 
RT are concerned about the risk of toxicity with bigger RT 
fields. Large-scale randomization of differing contouring 
volumes in a prospective clinical trial would be difficult 
given the inability to adequately control for the numerous 
prognostic covariates and diverse treatment options. To 
assess the impact of additional elective splenic/porta nodal 
RT on patients receiving chemoradiation for nonmetastatic 
GEJ carcinomas, we retrospectively compared locoregional 
versus extended locoregional RT volumes in terms of acute 
toxicities, postoperative complications, patterns of failure, 
and survival.
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MATERIALS AND METHODS
Patients
This retrospective analysis was approved by the 
Institutional Review Board. We initially identified 824 
patients with nonmetastatic GEJ carcinomas treated at a 
single institution with concurrent chemoradiation ± surgery, 
between 1998 and 2013. For consistency, staging was deter-
mined according to the 6th (2002) edition of the AJCC staging 
manual, using a combination of computed tomography, posi-
tron emission tomography/computed tomography, and esoph-
agoduodenoscopy/endoscopic ultrasound with FNA biopsy 
of suspicious lymph nodes. Most patients were treated with 
locoregional RT (n = 707) and fewer patients were treated 
with extended locoregional RT (n = 117).
Esophageal cancer was defined per AJCC 7th edition 
staging10 as 15 cm from the incisors to the GEJ and the proxi-
mal 5 cm of the stomach. A tumor was defined as esophageal 
(rather than gastric) carcinoma if its epicenter was in the lower 
thoracic esophagus or GEJ, or within the proximal 5 cm of the 
stomach with the tumor mass extending into the GEJ or dis-
tal esophagus. If the epicenter of the tumor was greater than 
5 cm distal to the GEJ, or within 5 cm of the GEJ but with no 
extension into the GEJ/esophagus, then the tumor was clas-
sified as gastric carcinoma and excluded from analysis. Only 
patients with GEJ esophageal carcinomas (including Siewert 
types I–III) were analyzed for this study.
Treatment
The CTV for locoregional RT volumes was defined as 
gross tumor volume (tumor + involved nodes) + elective cov-
erage of first echelon nodes and sometimes the celiac axis + 
3–4 cm superior/inferior margin + 1.0–1.5cm radial margin. In 
contrast, the CTV for extended locoregional RT volumes was 
defined as gross tumor volume + 3 cm mucosal expansion + 
elective coverage of celiac and splenic (±porta) nodes + addi-
tional 1.5 cm superior/inferior and 1.0 cm radial margin. The 
planning target volume used for statistical analyses for both 
RT groups was defined as CTV + 5 mm. Locoregional RT was 
delivered to a median dose of 50.4 Gy in 28 fractions, whereas 
extended locoregional RT was delivered to a median dose of 
45 Gy in 25 fractions. The RT treatment plan of each study 
patient was reviewed by a RT oncologist (JW) to ensure consis-
tency with the volumes described above. Illustrative examples 
of differences in locoregional versus extended locoregional 
RT volumes are shown in Figure 1. RT was delivered with 
three-dimensional conformal RT, intensity-modulated RT, or 
proton beam therapy and was based on physician preference.
Chemotherapy agents consisted of fluoropyrimidine (IV 
or oral), given alone or in combination with either a platinum 
compound (classified as FP) or a taxane (classified as FT). 
Types of surgical procedures included Ivor-Lewis esophagec-
tomy (with proximal gastrectomy and mediastinal + abdominal 
lymph node dissection), transthoracic esophagectomy, trans-
hiatal esophagectomy, three-field esophagectomy, and mini-
mally invasive esophagectomy, as well as total and subtotal 
gastrectomy (with esophageal margin and often modified D2 
lymph node dissection for Siewert type III tumors). Of the 411 
patients in the initial dataset (n = 824), who received trimodal-
ity therapy, most patients (Supplementary Table 1, SDC, http://
links.lww.com/JTO/A774) treated with locoregional RT had 
Ivor-Lewis (81%), followed by three-field (8%), trans-hiatal 
(7%), and minimally invasive esophagectomies (3%). In con-
trast, most patients treated with extended locoregional RT had 
Ivor-Lewis esophagectomies (47%) followed by total gastrec-
tomies (41%). Differences in surgery type were likely related 
to referral patterns, surgeon preference, RT volume, and loca-
tion of tumor/extent of gastric involvement, among others.
Definitions of Clinical Endpoints
All acute toxicities were graded according to Version 
4.0 of the NCI Common Terminology Criteria for Adverse 
Events and assessed on a weekly basis during chemoradiation 
treatment. All postoperative complications were recorded up 
to 30 days postoperatively. Postoperative gastrointestinal (GI) 
complications were defined as anastomotic leak, ileus, fistula, 
obstruction, or need for J-tube placement. Postoperative pul-
monary complications included pneumonia, ARDS, pleural 
effusions, and/or respiratory insufficiency. Cardiac complica-
tions included atrial fibrillation, any nonspecified arrhythmia, 
myocardial infarction, or development of congestive heart 
failure. Wound complications included wound erythema/
infection (requiring antibiotic treatment or re-opening/pack-
ing of wound) or dehiscence.
Dates of death were determined by reviewing clinical 
follow-up information in the patients’ medical records and 
Social Security Death Index. Overall survival (OS) was cal-
culated from date of diagnosis to date of last known vital sign. 
Patients alive at last follow-up date were administratively cen-
sored. Hospital records from radiographic studies, follow-up 
clinical examinations, surgical explorations, and endoscopy 
at every 3 month to 1 year intervals were used to assess dis-
ease progression, locoregional failure, and distant failure. 
Distant metastases progression-free survival (PFS) was com-
puted from the date of diagnosis to date of distant metastasis 
or death or last evaluation. Locoregional PFS was computed 
from the date of diagnosis to date of locoregional failure or 
death or last evaluation. Median follow-up time was compa-
rable for both groups (23 months).
Statistical Methods and Matching
Data were collected retrospectively. Associations 
between categorical variables and between continuous mea-
sures and categorical variables were assessed using either 
Fisher’s exact or generalized Fisher’s exact tests and Wilcoxon 
rank sum test.
To correct for bias, starting with the initial dataset 
of 824 patients, a subset of 222 patients were chosen con-
sisting of 111 matched pairs, one in each pair treated with 
locoregional and the other with extended locoregional RT. 
The pairs were obtained using a nearest neighbor match-
ing method.11,12 Variables used for matching included sex, 
tumor stage, performance status, histology, induction che-
motherapy, type of concurrent chemotherapy, RT modality, 
receipt of surgery, and type of surgery. Median year of ther-
apy for both matched groups was 2006. Nearest neighbor 
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matching also was used to produce a second dataset of 52 
(locoregional versus extended locoregional) pairs, matched 
by type II Siewert classification in addition to all previous 
covariates. Matching by type I and III Siewert classification 
could not be performed due to the rarity of these tumors 
among patients treated with extended locoregional and 
locoregional RT, respectively. Regression models stratified 
by matched pairs were fit to estimate the effect of locore-
gional versus extended locoregional RT on acute GI tox-
icity and postoperative complications (stratified logistic 
regression), and each type of PFS measure and OS (Cox 
proportional hazards regression models stratified by base-
line hazard). For matched pairs of binary variables, associa-
tion with locoregional versus extended locoregional RT was 
assessed using the McNemar mid-p test. Because many tests 
were performed, to control the overall false-positive rate, all 
nominal p values were adjusted for multiple testing via the 
Hochberg method.
RESULTS
Patient Characteristics
Table 1 summarizes baseline characteristics for all ini-
tial 824 GEJ patients and by locoregional versus extended 
locoregional RT volumes. Table 2 gives the corresponding 
summary for the 111 (locoregional versus extended locore-
gional) matched pairs, and shows that none of the base-
line covariates were statistically significantly different in 
the matched pair dataset. Among the 111 patients treated 
with extended locoregional RT, seven (6.3%), 51 (45.9%), 
and 53 patients (47.7%) had type 1, 2, and 3 Siewert GEJ 
carcinomas, respectively. Among the 111 patients treated 
with locoregional RT, 63 (56.8%), 47 (42.3%), and one 
patient (0.9%) had types 1, 2, and 3 Siewert GEJ carcino-
mas, respectively.
Impact of RT Volumes on Acute 
Toxicity during Chemoradiation
Please refer to Table 3. Compared with locoregional 
volumes, treatment with extended locoregional RT resulted in 
higher rates of grade 3 anorexia (adjusted p = 0.0178), grade 
3 dysphagia (adjusted p = 0.0010), and grade 3 esophagitis 
(adjusted p = 0.0511). There was also increased odds of acute 
grade 2+ GI toxicity, defined as a combination of weight loss, 
nausea/vomiting, fatigue, and/or anorexia, among patients 
treated with extended locoregional versus locoregional RT 
(OR: 2.92; adjusted p = 0.0447). In addition, five versus zero 
patients treated with extended locoregional versus locore-
gional RT, respectively, experienced a protracted RT course 
with prolonged number of days on treatment (unadjusted p = 
0.0313, adjusted p = 1.00).
Because the location of nodal metastasis largely 
depends on the location of the primary GEJ tumor, the vol-
ume of coverage may need to include a more extensive area 
in patients with more gastric-centric tumors. Thus, to normal-
ize the nodal risk between the two groups, we repeated the 
analyses among the subset of 104 patients (52 and 52 patients 
with locoregional and extended locoregional RT, respectively) 
with Siewert type II tumors. Although there continued to be 
a trend toward increased odds of acute grade 2+ GI toxicity 
with extended locoregional versus locoregional RT (OR: 2.00, 
unadjusted p = 0.13, adjusted p = 1.00), these results were not 
statistically significant.
Impact of RT Volumes on 
Postoperative Complications
As shown in Supplementary Table 1 (SDC, http://
links.lww.com/JTO/A774), there was a high association 
between type of surgery performed and locoregional versus 
extended locoregional RT volume. Although patients treated 
FIGURE 1.  Representative (A) extended locoregional radiation volumes with elective splenic ± porta nodal coverage (blue line 
demarcates the PTV), and (B) locoregional radiation volumes without elective splenic or porta nodal coverage (white line demar-
cates the PTV). PTV, planning target volume.
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TABLE 1.  Baseline Clinical and Treatment Characteristics for all Patients and by Extended Locoregional versus Locoregional RT
Measure
Type of Radiation Volume
All Patients (n = 824)
Extended Locoregional 
(n = 117) Locoregional (n = 707) Unadjusted p Valuea
Age at diagnosis (years)
  Mean 62.6 61.4 62.9 0.42b
  Minimum, maximum 21.0, 91.0 21.0, 85.0 22.0, 91.0
Gender, n (%)
  Male 725 (88) 93 (79) 632 (89) 0.0051c
Tumor stage, n (%)
  1 16 (2) 1 (1) 15 (2) 0.0045
  2 275 (34) 26 (23) 249 (36)
  3 449 (56) 82 (71) 367 (53)
  4a 64 (8) 6 (5) 58 (8)
  Missing 20 2 18
Tumor length (cm)
  N 714 90 624 0.56b
  Mean 5.4 5.6 5.4
  Minimum, maximum 1.0, 20.0 1.0, 13.0 1.0, 20.0
Karnofsky performance status
  Mean 84.5 85.6 84.3 0.08b
  Minimum, maximum 50.0, 100.0 60.0, 100.0 50.0, 100.0
Number of comorbidities
  Mean 1.1 1.1 1.1 0.94b
  Minimum, maximum 0, 5.0 0, 4.0 0, 5.0
Tumor differentiation, n (%)
  Well differentiated 6 (1) 1 (1) 5 (1) 0.58
  Moderate 324 (40) 42 (37) 282 (40)
  Poor 485 (60) 72 (63) 413 (59)
  Missing 9 2 7
Tumor histology, n (%)
  Adeno 745 (91) 114 (98) 631 (89) 0.0019
  Squamous 62 (8) 1 (1) 61 (9)
  Other 15 (2) 1 (1) 14 (2)
  Missing 2 1 1
Radiation therapy modality, n (%)
  3D 349 (42) 49 (42) 300 (42) <0.0001
  IMRT 349 (42) 67 (57) 282 (40)
  Proton 126 (15) 1 (1) 125 (18)
Induction chemotherapy, n (%)
  Yes 369 (45) 77 (66) 292 (41) <0.0001c
  No 455 (55) 40 (34) 415 (59)
Type of concurrent chemotherapy, n (%)
  FP 253 (31) 33 (28) 220 (31) 0.0116
  FT 422 (52) 51 (44) 371 (53)
  Other 143 (17) 32 (28) 111 (16)
  Missing 6 1 5
Type of surgery, n (%; surgery only)
  Trans-thoracic 2 (0.5) 2 (3) 0 <0.0001
  Ivor-Lewis 312 (76) 27 (47) 285 (81)
  Other 96 (23) 29 (50) 67 (19)
aGeneralized Fisher’s exact test.
bWilcoxon rank sum test.
cFisher’s exact test.
RT, radiation; IMRT, intensity-modulated RT; FP, fluoropyrimidine; FT, fluorotaxane; 3D, three-dimensional.
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TABLE 2.  Association Between Radiation Volume and Prognostic Covariates in the 222 Matched Patients
Measure
Type of Radiation Volume
All Pairs (n = 222)
Extended Locoregional 
(n = 111) Locoregional (n = 111) Unadjusted p Valuea
Age at diagnosis (years)
  Mean 61.3 61.4 61.1 0.91b
  Minimum, maximum 21.0, 87.0 21.0, 85.0 22.0, 87.0
Gender, n (%)
  Male 181 (82) 88 (79) 93 (84) 0.49c
Tumor stage, n (%)
  1 3 (1) 1 (1) 2 (2) 0.69
  2 53 (24) 25 (23) 28 (25)
  3 151 (68) 79 (71) 72 (65)
  4a 15 (7) 6 (5) 9 (8)
Tumor length (cm)
  n 182 86 96 0.62b
  Mean 5.5 5.6 5.4
  Minimum, maximum 1.0, 15.0 1.0, 13.0 1.0, 15.0
Karnofsky performance status
  Mean 85.9 85.7 86.2 0.53b
  Minimum, maximum 60.0, 100.0 60.0, 100.0 70.0, 100.0
Number of comorbidities
  Mean 1.1 1.1 1.1 0.44b
  Minimum, maximum 0, 5.0 0, 4.0 0, 5.0
Tumor differentiation, n (%)
  Well differentiated 1 (0.5) 1 (1) 0 0.78
  Moderate 78 (35) 40 (36) 38 (35)
  Poor 141 (64) 69 (63) 72 (65)
  Missing 2 1 1
Tumor histology, n (%)
  Adeno 220 (99) 110 (99) 110 (99) 1.00
  Squamous 2 (1) 1 (1) 1 (1)
  Other 0 0 0
Radiation therapy modality, n (%)
  3D 97 (44) 46 (41) 51 (46) 0.34
  IMRT 123 (55) 65 (59) 58 (52)
  Proton 2 (1) 0 2 (2)
Induction chemotherapy, n (%)
  Yes 135 (61) 73 (66) 62 (56) 0.17c
  No 87 (39) 38 (34) 49 (44)
Type of concurrent chemotherapy, n (%)
  FP 56 (25) 31 (28) 25 (23) 0.41
  FT 112 (50) 51 (46) 61 (55)
  Other 54 (24) 29 (26) 25 (23)
Type of surgery, n (%)
  None 112 (50) 56 (50) 56 (50) 1.00
  Ivor-Lewis 54 (24) 27 (24) 27 (24)
  Other 56 (25) 28 (25) 28 (25)
aGeneralized Fisher’s exact test.
bWilcoxon rank sum test.
cFisher’s exact test.
IMRT, intensity-modulated radiation; FP, fluoropyrimidine; FT, fluorotaxane; 3D, three-dimensional.
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with extended locoregional RT were more likely to undergo 
gastrectomies, patients treated with locoregional RT were 
more likely to undergo Ivor-Lewis and other esophagectomy 
approaches. Because the surgical approach commonly dif-
fered between patients treated in the two groups, comparison 
of postoperative complications required controlling for surgi-
cal differences between the two.
To account for these surgical differences, we matched 
by the exact type of surgery before assessing postoperative 
complication rates between the two (locoregional versus 
extended locoregional RT) groups. Because the only type of 
surgery that overlapped among those patients who received 
locoregional versus extended locoregional RT was Ivor-Lewis 
esophagectomy (Supplementary Table 1, SDC, http://links.
lww.com/JTO/A774), we could only analyze postop com-
plications among those patients who underwent Ivor-Lewis 
surgery (n = 27 matched pairs). In this subset analysis, after 
adjusting for multiple testing, locoregional versus extended 
locoregional RT had no impact on the rate of postoperative GI, 
pulmonary, cardiac, wound complications, or length of hospi-
tal stay (p > 0.05, Table 4).
Among patients with Siewert type II tumors, who 
underwent Ivor-Lewis surgery only (n = 16 matched pairs), 
again there was no difference between locoregional versus 
TABLE 3.  Acute CRT-Associated Toxicity among 111 Matched-Pair Patients Treated with Locoregional versus Extended 
Locoregional RT
Toxicity
Grade, n (%)
p Valuea Adjusted p Valued0 1–2 3
Weight loss
  Locoregional RT (n = 111) 54 (48) 55 (50) 2 (2) 0.62 1.00
  Extended locoregional RT (n = 108) 58 (54) 49 (45) 1 (1)
Nausea/vomiting
  Locoregional RT (n = 111) 37 (33) 66 (60) 8 (7) 0.0078 0.38
  Extended locoregional RT (n = 111) 20 (18) 72 (65) 19 (17)
Fatigue
  Locoregional RT (n = 111) 41 (37) 65 (59) 5 (4) 0.74 1.00
  Extended locoregional RT (n = 111) 40 (36) 63 (57) 8 (7)
Anorexia
  Locoregional RT (n = 111) 68 (61) 42 (38) 1 (1) 0.0003 0.0178
  Extended locoregional RT (n = 111) 47 (42) 51 (46) 13 (12)
Dysphagia
  Locoregional RT (n = 111) 23 (21) 82 (74) 6 (5) <0.0001 0.0010
  Extended locoregional RT (n = 111) 49 (44) 48 (43) 14 (13)
Esophagitis
  Locoregional RT (n = 111) 23 (21) 79 (71) 9 (8) 0.0010 0.0511
  Extended locoregional RT (n = 111) 45 (41) 52 (47) 14 (12)
Dermatitis
  Locoregional RT (n = 111) 67 (60) 44 (40) 0 (0) 0.0022c 0.11
  Extended locoregional RT (n = 111) 89 (80) 22 (20) 0 (0)
OR 95% CI p Valueb Adjusted p Valued
Acute GI toxicity Grade 2+ 2.92 1.56, 5.49 0.0008 0.0447
(Extended locoregional RT versus 
locoregional RT)
No, n (%) Yes, n (%) p Valuec Adjusted p Valued
Finished RT
  Locoregional RT (n = 111) 4 (4) 107 (96) 1.00 1.00
  Extended locoregional RT (n = 111) 4 (4) 107 (96)
Prolonged RT Coursee
  Locoregional RT (n = 111) 111 (100) 0 (0) 0.0313 1.00
  Extended locoregional RT (n = 111) 106 (95) 5 (5)    
aGeneralized Fisher’s exact test.
bFitted stratified logistic regression.
cMcNemar mid-p test.
dp Values adjusted using Hochberg method.
eProlonged RT course is defined as 2+ standard deviations longer than the mean elapsed days between start and end of RT treatment.
CI, confidence interval; CRT, chemoradiation; OR, odds ratio; RT, radiation.
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extended locoregional RT in the rate of postop GI (unadjusted 
p = 0.18, adjusted p = 1.00), pulmonary (unadjusted p = 0.45, 
adjusted p = 1.00), cardiac (unadjusted p = 0.69, adjusted p = 
1.00), wound/infection complications (unadjusted p = 0.0313, 
adjusted p = 1.00), or length of hospital stay (unadjusted p = 
0.0214, adjusted p = 0.97). Data are not shown.
Impact of RT Volumes on Patterns of Failure
Among the patients who underwent surgery (n = 55 
matched pairs), locoregional versus extended locoregional 
RT did not affect the pathologic T stage (unadjusted p = 0.48, 
adjusted p = 1.00), frequency of positive regional nodes on 
surgical specimen (36% versus 38%, unadjusted p = 0.83, 
adjusted p = 1.00), or rate of positive perigastric nodes on 
surgical specimen (15% versus 22%, unadjusted p = 0.38, 
adjusted p = 1.00). This remained true for the subset of 
patients (n = 16 matched pairs) with Siewert type II tumors.
Because one major difference between the RT volumes 
is elective coverage of celiac nodes, we analyzed differences in 
celiac relapse between the two. Patients who had celiac node 
involvement at diagnosis (n = 8) and those with missing data 
(n = 8) were excluded from analysis. Among the 203 remain-
ing patients, 28% and 100% of the patients treated with locore-
gional versus extended locoregional RT, respectively, received 
elective celiac RT. Patients treated with locoregional RT (n 
= 111) were more likely to receive elective celiac coverage 
if they had node positive or overall clinical stage 3+ disease, 
although these results were not statistically significant after 
adjusting for multiple testing (Supplementary Table 2, SDC, 
http://links.lww.com/JTO/A774). Of the 72 patients who did 
not receive elective celiac RT, two patients (2.8%) relapsed 
in the celiac nodes. Of the 124 patients who received elective 
celiac RT, two patients (1.6%) also relapsed in the celiac 
nodes. In three of these patients, the celiac failures repre-
sented the first site of recurrence and occurred simultaneously 
with distant metastases (Supplementary Table 3, SDC, http://
links.lww.com/JTO/A774). No patients failed in the splenic or 
porta nodes. Of note, the mean dose to the splenic hilum for 
those who received extended locoregional (n = 111) versus 
locoregional RT (n = 65 with evaluable RT plans) was 45 Gy 
versus 19 Gy (median 20 Gy, range 5–40 Gy), respectively.
Impact of RT Volumes on Survival Outcomes
Based on stratified Cox proportional hazards regression 
models on the 111 matched pairs, there was no association 
between locoregional versus extended locoregional volumes 
and OS, distant PFS, or locoregional PFS among the subset 
of patients who received surgery, those who received defini-
tive chemoradiation alone, and those with Siewert type 2 
tumors (Table 5).
DISCUSSION
Although there is growing evidence supporting the 
effectiveness of chemoradiation for the treatment of nonmeta-
static esophageal cancer,1–4 details regarding target volume 
delineation and RT fields have not been addressed in random-
ized controlled trials. This has led to variable RT volumes and 
elective nodal coverage used in recent trials.2,4,13 Thus, the goal 
of our current study was to assess whether additional coverage 
of regional splenic/porta nodes is necessary for the treatment 
of patients with GEJ tumors. Using matched pair analyses and 
adjustment for multiple testing, we found no differences in 
patterns of failure or survival between the two RT volumes, 
TABLE 4.  Postoperative Complications among Matched Pair Patients Treated with Extended Locoregional versus Locoregional RT
POC among 27 Matched Pairs Treated with Ivor-Lewis Surgery Only
Postoperative Complication Extended Locoregional RT Locoregional RT p Valuea Adjusted p Valuec
GI, n (%)
  Yes 9 (33) 4 (15) 0.15 1.00
  No 18 (67) 23 (85)
Pulmonary, n (%)
  Yes 14 (52) 10 (37) 0.30 1.00
  No 13 (48) 17 (63)
Cardiac, n (%)
  Yes 6 (22) 4 (15) 0.51 1.00
  No 21 (78) 23 (85)
Wound/infection, n (%)
  Yes 8 (31) 1 (4) 0.0039 0.20
  No 18 (69) 26 (96)
  Unknown 1 0
Length of hospital stay (days)
  n 26 27 0.0163b 0.75
  Mean 18.8 13.5
  Median 15 11
  Minimum, maximum 8.0, 76.0 7.0, 47.0
POC, postoperative complications; RT, radiation; GI, gastrointestinal.
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although acute GI toxicity was higher among patients treated 
with extended locoregional RT. Extended locoregional RT also 
resulted in more grade 3 dysphagia/esophagitis despite less RT 
dose; this may be related to more coverage of the stomach/liver 
and worse vomiting associated with extended locoregional RT 
leading to more reflux/acid-damage to the esophagus.
One of the important goals of chemoradiation is to 
reduce the primary tumor volume without increasing toxicity. 
However, achieving this goal hinges on defining the appropri-
ate RT volume. One obstacle to accurately defining the target 
for GEJ tumors include the controversy of whether GEJ tumors 
should be classified as gastric or esophageal tumors. The UICC 
TNM 6th edition classified GEJ tumors as gastric cancers14; but, 
the recent AJCC TNM classification changed the categoriza-
tion of GEJ tumors, such that all tumors located within 5 cm 
below the GEJ and infiltrating the junction are now classified 
as esophageal cancers. Thus, all Siewert types I, II, and III GEJ 
tumors are considered and staged as esophageal cancers.
This debate on which Siewert type of GEJ carcinomas 
should be classified as esophageal versus gastric cancers is 
important because patterns of spread and failure differ between 
esophageal versus gastric primaries. Although NCCN recom-
mends Siewert type I and II tumors to be generally managed 
with RT guidelines applicable to esophageal cancers and type 
III tumors to be managed with guidelines applicable to either 
esophageal or gastric cancers, these represent category 2A 
recommendations with lower level of evidence. Overall, it 
is probably most accepted that type I GEJ tumors should be 
treated as distal esophageal carcinomas, but how type II and III 
GEJ tumors should be treated are more controversial.9,15 The 
EORTC expert opinion14 and another pathological review16 
of the location and frequency of recurrences suggested elec-
tive nodal coverage of para-esophageal, perigastric, and celiac 
nodes for type I GEJ tumors, but differ from NCCN and our 
study results by recommending additional splenic nodal cov-
erage for type II/III GEJ tumors. However, those recommen-
dations were based on out-dated patterns of failure data from 
patients not treated with more modern techniques and often 
do not account for possible eradiaction of microscopic nodal 
disease with neadjuvant chemoradiation or subsequent sur-
gery. Moreover, the recommendations were not based on stud-
ies that directly compared whether difference in elective nodal 
coverage with RT would impact patterns of failure.
To more clearly define a RT target volume for GEJ 
tumors, our study compared locoregional versus extended 
locoregional RT volumes in terms of toxicity and clinical out-
comes. Because locoregional volumes resulted in less acute 
chemoradiation-associated GI toxicity without compromis-
ing relapse/survival, our results suggest that coverage of first-
echelon and celiac nodes alone may be adequate for Siewert 
type I/II GEJ tumors. We cannot draw definitive conclusions 
on whether type III tumors should be treated with locoregional 
versus extended locoregional RT, because only one patient with 
type III tumor was treated with locoregional RT. With respect 
to whether the celiac axis should receive elective coverage for 
GEJ carcinomas, while we confirm previously published find-
ings17 in that celiac relapse was rare regardless of whether the 
patient received elective celiac RT, there may have been selec-
tion bias in determining who received elective celiac coverage 
among those treated with locoregional RT (Supplementary 
Table 2, SDC, http://links.lww.com/JTO/A774). Other poten-
tial reasons for why some but not all patients were chosen for 
elective celiac coverage among those who received locore-
gional RT cannot be fully elucidated. This selection bias, in 
combination with the lack of effective salvage treatments for 
celiac failures, would caution against omitting prophylactic 
celiac treatment in GEJ tumors. Given that no patients failed 
in the porta or splenic nodes, however, our results do suggest 
that omission of porta/splenic regional nodal coverage may be 
safe in type I–II GEJ tumors. Although we acknowledge that 
patients who did not receive elective splenic coverage still got 
an incidental low scatter dose to the splenic hilum, which may 
or may not have contributed to disease control, our study still 
suggests that treating splenic nodes to high dose is not neces-
sary given comparable disease control and reduced toxicity 
with omission of elective coverage.
Our study is subject to limitations intrinsic to a retro-
spective dataset. First, patients were not randomized between 
TABLE 5.  Fitted Conditional Cox Models Assessing Effect of Extended Locoregional versus Locoregional RT on Survival Outcomes
Outcome # Matched Pairs HR 95% CI p Value Adjusted p Value*
Survival outcomes among all extended locoregional versus locoregional RT matched pairs
  Overall survival 109 0.97 0.62, 1.54 0.91 1.00
  PFS—distant metastasis 86 1.1 0.67, 1.78 0.71 1.00
  PFS—local regional control 71 0.86 0.50, 1.48 0.58 1.00
Survival outcomes among extended locoregional versus locoregional RT matched pairs treated with surgery
  Overall survival 54 0.78 0.39, 1.56 0.48 1.00
  PFS—distant metastasis 42 0.93 0.45, 1.93 0.85 1.00
  PFS—local regional control 39 0.67 0.30, 1.48 0.32 1.00
Survival outcomes among extended locoregional versus locoregional RT matched pairs treated with definitive CRT
  Overall survival 55 1.16 0.63, 2.14 0.64 1.00
  PFS—distant metastasis 44 1.25 0.65, 2.41 0.51 1.00
  PFS—local regional control 32 1.08 0.51, 2.29 0.85 1.00
HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; RT, radiation.
*p Values adjusted using the Hochberg method.
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RT fields and consequently, correction of many potential 
biases was needed. Although we were able to obtain closely 
matched pairs to correct for biases of known variables, pos-
sible effects of additional external confounding factors cannot 
be excluded. Initially, we considered alternative methods of 
correcting for bias, including stratification and inverse prob-
ability of treatment weights analysis. However, there were far 
too many strata to analyze feasibly; and, inverse probability 
of treatment weights was not possible because of high collin-
earity among many prognostic covariates and other treatment 
variables, which made estimation of propensity scores unre-
liable. Second, RT doses and techniques were not standard-
ized. Third, physician and surgeon treatment bias is inherent in 
any retrospective analysis. Finally, the relatively small sample 
sizes used in the subset analyses limit the reliability of any 
conclusions.
Nevertheless, because a randomized trial to compare 
RT field coverage based on Siewert grouping is unlikely to be 
conducted, our study offers a limited but worthwhile attempt 
to delineate the ideal target volume for GEJ tumors. In conclu-
sion, our data suggest that selected type I and II nonmetastatic 
GEJ tumors can be treated sufficiently with elective coverage 
of adjacent para-esophaegal (RTOG nodal station 8), peri-
gastric (RTOG nodal station 15–17), and celiac lymph nodes 
(RTOG nodal station 20); elective inclusion of more regional 
splenic/porta nodes (RTOG nodal stations 19/18) can be safely 
omitted from the CTV. Whether type III GEJ tumors can be 
treated with locoregional or more conventional extended 
locoregional RT volumes needs further investigation.
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